Exhibit 10.20

                          SECURITIES PURCHASE AGREEMENT

         Securities Purchase Agreement (together with the schedules and exhibits
hereto, this "Agreement"),  dated as of October __, 2003, by and between Enhance
Biotech,  Inc., a Delaware corporation (the "Company"),  and each of the Persons
(as defined below) who has executed a signature  page to this Agreement  (each a
"Purchaser," and together, the "Purchasers").


                              W I T N E S S E T H:

         WHEREAS,  the Company desires to issue and sell to the Purchasers,  and
the Purchasers desire to purchase from the Company, the Securities (as such term
is defined below) as set forth below.

         NOW,  THEREFORE,  in  consideration  of the foregoing  premises and the
mutual covenants and agreements  hereinafter  contained,  and for other good and
valuable  consideration,  the  receipt  and  sufficiency  of  which  are  hereby
acknowledged,  intending to be legally bound, the parties hereto hereby agree as
follows:

         1. Authorization and Sale of Securities.

         1.1  Authorization.  The Company has duly  authorized  the issuance and
sale of $2,000,000 of shares of its Common Stock,  par value $0.001 per share at
a price of $1.50 per share (the "Common Stock").  The Company is offering shares
of the Common Stock  Securities  (the  "Offering") for sale only to individuals,
entities  or  groups,  including,  without  limitation,   corporations,  limited
liability   companies,   limited  or  general   partnerships,   joint  ventures,
associations,  joint stock companies, trusts, unincorporated  organizations,  or
governments or any agencies or political subdivisions thereof (each, a "Person")
who are  "accredited  investors" (as defined  herein).  Each Purchaser of Common
Stock in this  Offering  shall  receive  Common  Stock  Purchase  Warrants  (the
"Purchase  Warrants")  to purchase an  aggregate  number of shares of the Common
Stock  equal to one  hundred  percent  (100%) of the  number of shares of Common
Stock  purchased by such  Purchaser in the  Offering,  exercisable  at $1.50 per
share,  such warrants to be  exerciseable  for a period of 5 years from closing.
The Purchase Warrants are sometimes  hereinafter  referred to as the "Warrants."
The Common  Stock and the  Warrants  offered  hereby are  sometimes  hereinafter
referred to as the "Securities". The Purchasers of the Securities shall have the
benefit  of piggy  back  registration  rights in respect of the shares of Common
Stock  underlying  the  Securities.  The  Company is making the  Offering of the
Securities  directly  through its officers and its directors.  Each purchaser of
Common  Stock  in this  offering  shall  have  the  right  to make an  identical
investment at any time within 6 months of the date hereof, on the same terms and
conditions.  Should the Company  achieve agreed  milestones at any time within 6
months of the date hereof,  the Company will give 14 days notice to subscribe to
each  purchaser.  Should each  purchaser not  subscribe  after the 14 day notice
period, then the purchaser will lose the right to make the identical investment.

         1.2      Subscription.

         Subject  to the  terms  and  conditions  hereinafter  set forth in this
Agreement,  each  Purchaser  hereby offers to purchase,  at a price of $1.50 per
share,  the  number  of shares of  Common  Stock  set  forth  beneath  each such
Purchaser's  name on the  signature  pages of this  Agreement,  for an aggregate
purchase price (the "Purchase Price") to be paid by such Purchaser in the amount
set forth on the signature page beneath such Purchaser's name.

         1.3  Subscription  Procedures.   To  submit  this  Subscription,   each
Purchaser must deliver (i) this Agreement,  including,  without limitation,  the
Purchaser  Questionnaire  accompanying  this Agreement,  both duly completed and
executed, to the following address, unless otherwise advised by the Company:

                           16th Floor, 666 Third Avenue
                           New York, New York  10017
                           Attention:  Christopher Every, CEO
                           Telephone:  (212) 561 1716
                           Facsimile:  (212) 697 1985





         Attention:  Compliance (re Enhance Biotech, Inc.)

         (with any questions to be raised with Chris Every at (212) 554-4158)

         The Company may accept or reject subscriptions, in whole or in part, or
accept subscriptions for less than the $50,000 minimum subscription, in its sole
discretion.  The Company shall notify each Purchaser of the portion,  if any, of
such Purchaser's subscription which has been accepted,  payment instructions for
the purchase price,  including wire transfer  instructions  and instructions for
delivery  of  payment  by  checks,  if  applicable,  and the date upon which the
applicable  Closing shall be held and payment must be made.  At each  applicable
Closing,  each Purchaser acquiring  Securities at such Closing shall deliver and
pay the applicable  purchase price in full for the Securities being purchased by
such Purchaser at such Closing,  in the amount of $1.50 for each share of Common
Stock  for  which  such  Purchaser's  subscription  has been  accepted,  in U.S.
dollars,  in  immediately  available  funds,  in  accordance  with  the  payment
instructions contained in the notification to such Purchaser by the Company.

         2. Closing.

         Upon acceptance of subscriptions  for Common Stock totaling  $2,000,000
the Company shall hold a closing of the purchase and sale of such Securities.

         3. Conditions to the Obligations of each Purchaser at Closing.

         The obligation of each Purchaser to purchase and pay for the Securities
subscribed  for by such  Purchaser at the  applicable  Closing is subject to the
satisfaction  on or  prior to the  Closing  Date,  as the  case  may be,  of the
following conditions, each of which may be waived by the applicable Purchaser:

         3.1 Representations and Warranties.  The representations and warranties
of the Company contained in this Agreement which are qualified as to materiality
must be true and correct in all respects and the  representations and warranties
of the  Company  contained  in this  Agreement  which  are not  qualified  as to
materiality must be true and correct in all material  respects as of the Closing
Date except to the extent that the  representations  and warranties relate to an
earlier date in which case the  representations  and warranties must be true and
correct as written or true and correct in all material respects, as the case may
be, as of the earlier date.

         3.2  Performance  of  Covenants.  The Company  shall have  performed or
complied with in all material respects all covenants and agreements  required to
be  performed  by it on or  prior to the  applicable  Closing  pursuant  to this
Agreement,   including,   without  limitation,   the  delivery  of  certificates
evidencing the Securities issued to the Purchasers at the Closing.

         3.3 No Injunctions;  etc. No court or governmental injunction, order or
decree  prohibiting  the purchase and sale of the Securities  will be in effect.
There  will  not be in  effect  any  law,  rule  or  regulation  prohibiting  or
restricting the sale or requiring any consent or approval of any Person that has
not been obtained to issue and sell the Securities to the Purchasers.

         3.4 Closing Documents.  At Closing, the Company shall have delivered to
each applicable Purchaser the following:

         (a) a certificate of the President of the Company  certifying  that the
conditions in Sections 3.1, 3.2 and 3.3 have been satisfied;

         (b) a certificate,  accompanied by the applicable Warrants,  evidencing
the Securities purchased by such Purchaser; and


         3.6 Waivers and Consents. Except as set forth in the next sentence, the
Company will have  obtained  all  consents and waivers  necessary to execute and
deliver this Agreement and all related documents and agreements and to issue and
deliver the  Securities,  and all consents and waivers will be in full force and
effect.




         4. Conditions to the Obligations of the Company at Closing.

         The  obligation of the Company to issue and sell the  Securities to any
Purchaser is subject to the satisfaction on or prior to each Closing Date of the
following conditions, each of which may be waived by the Company:

         4.1 Representations and Warranties.  The representations and warranties
of  the  Purchaser  contained  in  this  Agreement  which  are  qualified  as to
materiality must be true and correct in all respects and the representations and
warranties of the Purchasers contained in this Agreement which are not qualified
as to  materiality  must be true and correct in all material  respects as of the
applicable Closing Date.

          4.2  Performance of Covenants.  The Purchasers  will have performed or
complied with in all material respects all covenants and agreements  required to
be  performed  by the  Purchasers  on or prior to the  Closing  pursuant to this
Agreement.

         4.3 Purchaser  Questionnaire.  All of the information furnished by such
Purchaser  in  the  confidential  purchaser   questionnaire   accompanying  this
Agreement (the "Purchaser  Questionnaire") shall have been accurate and complete
in all material respects.

         4.4 No  Injunctions.  No court  or  governmental  injunction,  order or
decree prohibiting the purchase or sale of the Securities will be in effect.

         4.5  Closing  Documents.  The  Purchasers  will have  delivered  to the
Company this  Agreement  and a  purchasers  questionnaire  duly  executed by the
Purchasers.

         5. Representations and Warranties of each Purchaser.

         Each  Purchaser,  in  order to  induce  the  Company  to  perform  this
Agreement,  hereby  represents  and  warrants,  severally  and not  jointly,  as
follows:

         5.1 Due Authorization.  Each Purchaser represents for such Purchaser to
the Company that such  Purchaser  has full power and authority and has taken all
action  necessary to authorize  such  Purchaser to execute,  deliver and perform
such Purchaser's obligations under this Agreement.  This Agreement is the legal,
valid and binding obligation of such Purchaser in accordance with its terms.

         5.2 Accredited Investor.  Each Purchaser represents that such Purchaser
is an  Accredited  Investor as that term is defined in  Regulation D promulgated
under the Securities Act of 1933, as amended (the "Securities Act").

         5.3  No  Investment   Advice.  The  Company  has  not  made  any  other
representations  or warranties to such Purchaser  other than as set forth herein
or incorporated  herein by reference with respect to the Company or rendered any
investment advice.

         5.4  Investment   Experience.   Each  Purchaser  represents  that  such
Purchaser has not  authorized  any Person to act as such  Purchaser's  Purchaser
Representative (as that term is defined in Regulation D of the General Rules and
Regulations under the Securities Act) in connection with this transaction.  Such
Purchaser  has such  knowledge  and  experience  in  financial,  investment  and
business  matters that such  Purchaser is capable of  evaluating  the merits and
risks of the  prospective  investment  in the  securities  of the Company.  Such
Purchaser has consulted with such independent legal counsel or other advisers as
such Purchaser has deemed appropriate to assist such Purchaser in evaluating the
proposed investment in the Company.

         5.5 Adequate Means. Each Purchaser represents as to such Purchaser that
such Purchaser (i) has adequate means of providing for such Purchaser's  current
financial  needs and  possible  contingencies;  and (ii) can  afford (a) to hold
unregistered  securities for an indefinite  period of time as required;  and (b)
sustain a complete loss of the entire amount of the subscription.




         5.6  Access  to  Information.   Each  Purchaser  represents  that  such
Purchaser  has been  afforded the  opportunity  to ask questions of, and receive
answers from the officers  and/or  directors of the Company acting on its behalf
concerning  the terms  and  conditions  of this  transaction  and to obtain  any
additional   information,   to  the  extent  that  the  Company  possesses  such
information or can acquire it without unreasonable effort or expense,  necessary
to  verify  the  accuracy  of  the  information  furnished;  and  has  had  such
opportunity  to the extent  such  Purchaser  considers  appropriate  in order to
permit such  Purchaser to evaluate the merits and risks of an  investment in the
Company.  It is understood that all documents,  records and books  pertaining to
this investment have been made available for inspection,  and that the books and
records of the Company will be available upon  reasonable  notice for inspection
by  investors  during  reasonable  business  hours  at its  principal  place  of
business.  The foregoing  shall in no way be deemed to limit the ability of each
Purchaser  to rely on the  representations  and  warranties  set forth herein or
incorporated herein by reference.

         5.7 No Endorsement.  Each Purchaser further acknowledges that the offer
and  sale of the  Securities  has not been  passed  upon or the  merits  thereof
endorsed or approved by any state or federal authorities.

         5.8  Non-Registered  Securities.  Each Purchaser  acknowledges that the
offer and sale of the Securities have not been  registered  under the Securities
Act or any state securities laws and the Securities and the underlying shares of
Common  Stock  may be  resold  only if  registered  pursuant  to the  provisions
thereunder or if an exemption  from  registration  is available.  Each Purchaser
understands  that the offer and sale of the  Securities is intended to be exempt
from   registration   under  the  Securities  Act,  based,  in  part,  upon  the
representations,  warranties and agreements of such Purchaser  contained in this
Agreement.

         5.9 No Resale.  Each Purchaser  represents  that the  Securities  being
subscribed  for,  and the  securities  underlying  the  subscription,  are being
acquired  solely  for  the  account  of  such  Purchaser  for  such  Purchaser's
investment  and not  with a view to,  or for  resale  in  connection  with,  any
distribution  in any  jurisdiction  where  such  sale or  distribution  would be
precluded. By such representation, such Purchaser means that no other Person has
a  beneficial  interest  in the  Securities  or the  securities  underlying  the
subscription, and that no other Person has furnished or will furnish directly or
indirectly,   any  part  of  or  guarantee  the  payment  of  any  part  of  the
consideration  to be  paid  by  such  Purchaser  to the  Company  in  connection
therewith.  Such  Purchaser does not intend to dispose of all or any part of the
Securities or the securities  underlying the  subscription  except in compliance
with the provisions of the Securities Act and applicable  state securities laws,
and  understands   that  the  Securities  and  the  securities   underlying  the
subscription  are being  offered  pursuant  to a  specific  exemption  under the
provisions  of the  Securities  Act,  which  exemption(s)  depends,  among other
things, upon the compliance with the provisions of the Securities Act.

         5.10 Legend.  Each Purchaser  hereby  acknowledges  and agrees that the
Company  may  insert  the  following  or  similar  legend  on  the  face  of the
certificates  evidencing  the  Securities  purchased by such  Purchaser  and the
shares of Common Stock issued upon the exercise of the Warrants, as the case may
be, if required in compliance with the Securities Act or state securities laws:

         "These  securities have not been registered under the Securities Act of
         1933, as amended (the  "Securities  Act"), or any state securities laws
         and may not be sold or  otherwise  transferred  or  disposed  of except
         pursuant to an effective  registration  statement  under the Securities
         Act and any applicable  state securities laws, or an opinion of counsel
         satisfactory   to  counsel  to  the  issuer  that  an  exemption   from
         registration  under the act and any applicable state securities laws is
         available."

         5.11  Broker's  or  Finder's  Commissions.  No finder,  broker,  agent,
financial  person or other  intermediary has acted on behalf of any Purchaser in
connection with the sale of the Securities by the Company or the consummation of
this Agreement or any of the transactions contemplated hereby.

         Each Purchaser certifies that each of the foregoing representations and
warranties by such Purchaser set forth in this Section 5 are true as of the date
hereof and shall survive such date.

         6. Representations and Warranties of the Company.

         The Company represents and warrants to the Purchasers as follows:




         6.1  Organization,  Good Standing and  Qualification.  The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware.  The Company has full corporate power and authority to
own and hold its  properties  and to conduct its  business.  The Company is duly
licensed or qualified to do business, and in good standing, in each jurisdiction
in which the nature of its business  requires  licensing,  qualification or good
standing,  except for any  failure to be so  licensed  or  qualified  or in good
standing  that would not have a material  adverse  effect on the  Company or its
results  of  operations,  assets or  financial  condition  or on its  ability to
perform its  obligations  under this  Agreement  or to issue the  Securities  (a
"Material Adverse Effect").

         6.2 Capitalization. As of the date hereof, the authorized capital stock
of the Company  consists of 25,000,000  shares of Common Stock, par value $0.001
per share (the "Common Stock").  As of the date hereof, (i) 16,839,900 shares of
Common Stock were issued and  outstanding,  (ii) except as set forth  below,  no
shares of Common Stock were reserved for issuance  upon exercise of  outstanding
options issued to persons other than shares  reserved for issuance upon exercise
of options  issued to officers of the Company,  (iii) except as set forth below,
no shares of Common  Stock were  reserved  for  issuance  upon the  exercise  of
outstanding warrants and (iv) Company is offering 1,333,333 shares of its Common
Stock in the  Offering  and the  accompanying  Warrants,  and is  reserving  for
issuance  upon  exercise  of the  Warrants  1,333,333  shares  of  Common  Stock
underlying such Warrants as of this date. All the  outstanding  shares of Common
Stock  have been duly  authorized  and  validly  issued  and are fully  paid and
nonassessable  and free of preemptive  rights created by or through the Company,
and have been issued in compliance with all federal and state  securities  laws,
and were not issued in violation of any  preemptive  rights or similar rights to
subscribe for or purchase  securities.  Except as set forth in this Section 6.2,
including without  limitation the next succeeding  sentence,  there are no other
options, warrants or other rights, convertible debt, agreements, arrangements or
commitments of any character  obligating the Company to issue or sell any shares
of capital  stock of or other  equity  interests  in the  Company  other than to
officers of the Company.  The Company has an  outstanding  warrant for 1,000,000
shares,  issued to Jano Holdings Limited,  exercisable at a purchase price equal
to the  Purchase  Price for each share of Common  Stock  sold in this  offering,
which  warrant  expires  February  22nd,  2008.  The Company is not obligated to
retire,  redeem,  repurchase or otherwise  reacquire any of its capital stock or
other securities. Except as disclosed in this Section 6.2 and as contemplated by
this Agreement, there are no stockholders agreements, voting agreements or other
similar  agreements  with  respect to the Common Stock to which the Company is a
party.  Except as contemplated by this Agreement,  the Company does not directly
or indirectly  own or have any investment in any of the capital stock of, or any
other  proprietary  interest  in, any Person  other  than  Enhance  Lifesciences
Limited,  a  corporation  organized  under the laws of the United  Kingdom,  and
Enhance Lifesciences Inc., a Delaware Corporation. The Company has not adopted a
stockholders rights plan, poison pill or similar arrangement.

         6.3 Corporate Power, Authorization; Enforceability. Except as otherwise
expressly  stated in this  Agreement,  the Company has full corporate  power and
authority to execute, deliver and enter into this Agreement, and the instruments
evidencing  the Warrants  (collectively,  the  "Transaction  Documents")  and to
consummate the transactions contemplated hereby and thereby. Except as otherwise
expressly stated in this Agreement,  all action on the part of the Company,  its
directors or stockholders necessary for the authorization,  execution,  delivery
and performance of the Transaction  Documents by the Company, the authorization,
sale,  issuance  and  delivery  of the  Securities  contemplated  hereby and the
performance  of the  Company's  obligations  hereunder and  thereunder  has been
taken. Except as otherwise expressly stated in this Agreement, the Securities to
be purchased  on each the Closing  Date and the shares of Common Stock  issuable
upon the exercise of the Warrants have been duly  authorized and, when issued in
accordance  with  this  Agreement,  will  be  validly  issued,  fully  paid  and
nonassessable and will be free and clear of any mortgage, deed of trust, pledge,
hypothecation, assignment, encumbrance, lien (statutory or other) or preference,
priority,  right or other security  interest or preferential  arrangement of any
kind  or  nature   whatsoever   (excluding   Common  stock  and  equity  related
preferences)  (collectively,  "Liens")  imposed by or through the Company  other
than restrictions imposed by the Transaction Documents and applicable securities
laws.  No  preemptive  or other  rights  to  subscribe  for or  purchase  equity
securities  of the Company  exists with  respect to the issuance and sale of the
Securities or the shares of Common Stock issuable upon exercise of the Warrants.
Except  as  otherwise  expressly  stated  in  this  Agreement,  the  Transaction
Documents  have been duly executed and delivered by the Company,  and constitute
the legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms,  except as enforceability may be limited
by applicable bankruptcy, insolvency,  reorganization,  fraudulent conveyance or
transfer,  moratorium or similar laws  affecting the  enforcement  of creditors'
rights generally and by general  principles of equity relating to enforceability
(regardless of whether considered in a proceeding at law or in equity).




         6.4 Litigation.  There are no claims, actions, suits, investigations or
proceedings  pending  or, to the  Company's  knowledge,  threatened  proceedings
against the Company or its respective  assets, at law or in equity, by or before
any Governmental  Authority,  or by or on behalf of any third party,  except for
any claim,  action,  suit,  investigation  or proceeding  which would not have a
Material  Adverse  Effect nor does the Company have  knowledge that there is any
reasonable basis for any of the foregoing.  There are no claims, actions, suits,
investigations or proceedings pending or, to the Company's knowledge, threatened
proceedings  against  the  Company  contesting  the right of the Company to use,
sell,  import,  license,  or make  available to any Person any of the  Company's
products or services  currently or previously  sold,  offered,  licensed or made
available  to any Person or used by the  Company or opposing  or  attempting  to
cancel any of the Company's  Intellectual Property rights, except for any claim,
action,  suit,  investigation  or  proceeding  which  would not have a  Material
Adverse Effect.

         6.5 Compliance with Laws; No Default or Violation; Contracts. Except as
otherwise contemplated by this Agreement in respect of the Special Participation
Warrants,  the  Company  is in  compliance  in all  material  respects  with all
Requirements of Law and all orders issued by any court or Governmental Authority
against the Company in all material respects. To the Company's knowledge,  there
is no existing or currently  proposed  Requirement of Law which could reasonably
be expected to prohibit or restrict the Company  from,  or otherwise  materially
adversely affect the Company in,  conducting its business in any jurisdiction in
which it now conducts or proposes to conduct such business.  The Company has all
material  licenses,   permits  and  approvals  of  any  Governmental   Authority
(collectively,  "Permits") that are necessary for the conduct of the business of
the  Company;  (ii) such  Permits  are in full  force and  effect;  and (iii) no
violations  are or have been  recorded  in respect of any  Permit.  No  material
expenditure  is  presently  required by the Company to comply with any  existing
Requirements of Law or order. Except as would not be reasonably expected to have
a  Material  Adverse  Effect,  the  Company  is not (i) in  default  under or in
violation of any indenture,  loan or credit  agreement or any other agreement or
instrument  to which it is a party  of by which it or any of its  properties  is
bound or (ii) in  violation  of any  order,  decree or  judgment  of any  court,
arbitrator  or other  Governmental  Authority.  The  contracts  described in the
Commission  Documents or incorporated by reference  therein that are material to
the Company (collectively,  the "Contractual Obligations") are in full force and
effect on the date  hereof,  and  neither  the  Company  nor,  to the  Company's
knowledge,  any other party to such  contracts is in breach of or default  under
any of such contracts nor, to the Company's knowledge,  does any condition exist
that with  notice or lapse of time or both  would  constitute  a default by such
other party thereunder.  The Company has not received notice of a default and is
not in default under or, with respect to, any Contractual Obligation nor, to the
Company's knowledge,  does any condition exist that with notice or lapse of time
or  both  would  constitute  a  default  thereunder.  All  of  such  Contractual
Obligations are valid, subsisting, in full force and effect and binding upon the
Company and, to the  Company's  knowledge,  the other parties  thereto,  and the
Company has paid in full or accrued all amounts due thereunder and has satisfied
in full or provided for all of its liabilities and obligations thereunder.

         6.6  Insurance.  The Company  maintains  and will  continue to maintain
insurance of the types and in the amounts that the Company  reasonably  believes
is adequate for its business,  including, but not limited to, insurance covering
all real and personal  property  owned or leased by the Company  against  theft,
damage,  destruction,  acts of vandalism and all other risks customarily insured
against by similarly situated companies, all of which insurance is in full force
and effect.

         6.7  Environmental  Matters.  The  Company  is in  compliance,  in  all
material respects,  with all applicable  Environmental  Laws. There is no civil,
criminal or administrative  judgment,  action,  suit,  demand,  claim,  hearing,
notice of violation, investigation,  proceeding, notice or demand letter pending
or, to the  Company's  knowledge,  threatened  against the  Company  pursuant to
Environmental  Laws.  To the Company's  knowledge,  there are no past or present
events, conditions, circumstances, activities, practices, incidents, agreements,
actions or plans which could reasonably be expected to prevent  compliance with,
or which have given rise to or will give rise to  liability  which  would have a
Material  Adverse  Effect,   under  Environmental  Laws.  For  purposes  of  the
foregoing,  "Environmental  Laws" means federal,  state, local and foreign laws,
principles  of common  laws,  civil  laws,  regulations,  and codes,  as well as
orders,  decrees,  judgments or injunctions,  issued,  promulgated,  approved or
entered  thereunder  relating to  pollution,  protection of the  environment  or
public health and safety.

         6.8  Taxes.  The  Company  has  paid  or  caused  to be  paid,  or  has
established reserves in accordance with GAAP for all Tax liabilities  applicable
to the Company for all fiscal years that have not been  examined and reported on
by the taxing authorities (or closed by applicable statutes).  No additional Tax
assessment against the Company has been heretofore proposed or, to the Company's
knowledge,  threatened by any Governmental Authority for which provision has not
been made on its balance sheet.




         No tax  audit is  currently  in  progress  and  there is no  unassessed
deficiency  proposed  or, to the  Company's  knowledge,  threatened  against the
Company.  The  Company has no  knowledge  of any change in the rates or basis of
assessment  of any Tax (other than  federal  income tax),  of the Company  which
would reasonably be expected to have a Material Adverse Effect.  The Company has
not agreed to or is required to make any  adjustments  under  section 481 of the
Code by reason of a change of accounting method or otherwise. None of the assets
of the Company is  required  to be treated as being  owned by any Person,  other
than the  Company  or any of its  subsidiaries,  pursuant  to the "safe  harbor"
leasing  provisions  of  Section  168(f)(8)  of the Code.  The  company is not a
"United States real property  holding  corporation" (a "USRPHC") as that term is
defined  in  Section  897(c)(2)  of the  Code  and the  regulations  promulgated
thereunder.

         For purposes of this Agreement,  "Code" means the Internal Revenue Code
of 1986, as amended, and "Taxes" means any federal, state,  provincial,  county,
local, foreign and other taxes (including,  without limitation, income, profits,
windfall profits,  alternative,  minimum, accumulated earnings, personal holding
company, capital stock, premium, estimated, excise, sales, use, occupancy, gross
receipts, franchise, ad valorem, severance, capital levy, production,  transfer,
withholding,  employment, unemployment compensation, payroll and property taxes,
import duties and other  governmental  charges and assessments),  whether or not
measured  in  whole  or in  part  by net  income,  and  including  deficiencies,
interest,  additions to tax or interest, and penalties with respect thereto, and
including expenses  associated with contesting any proposed  adjustments related
to any of the foregoing.

         6.9      Intellectual Property.

              (a)  "Intellectual  Property"  shall mean all of the  following as
they are necessary in  connection  with the business of the Company as presently
conducted and as they exist in all  jurisdictions  throughout the world, in each
case,  to the extent  owned by or licensed to the Company:  (i) patents,  patent
applications  and  inventions,  designs and  improvements  described and claimed
therein, patentable inventions and other patent rights (including any divisions,
continuations, continuations-in-part, reissues, reexaminations, or interferences
thereof,  whether or not patents are issued on any such applications and whether
or  not  any  such  applications  are  modified,   withdrawn,   or  resubmitted)
("Patents");  (ii) trademarks,  service marks,  trade dress,  trade names, brand
names,  designs,  logos, or corporate names, whether registered or unregistered,
and all registrations and applications for registration thereof  ("Trademarks");
(iii) copyrights and mask works,  including all renewals and extensions thereof,
copyright   registrations  and  applications  for  registration   thereof,   and
non-registered  copyrights  ("Copyrights");   (iv)  trade  secrets,  inventions,
know-how,  process technology,  databases,  confidential  business  information,
customer  lists,  technical data and other  proprietary  information  and rights
("Trade   Secrets");   (v)  computer  software  programs,   including,   without
limitation,  all source code,  object code, and  documentation  related  thereto
("Software");  (vi) Internet  addresses,  domain names, web sites, web pages and
similar  rights  and  items  ("Internet   Assets");   and  (vii)  all  licenses,
sublicenses and other  agreements or permissions  including the right to receive
royalties,  or any other  consideration  related to the  property  described  in
(i)-(vi).  The Intellectual  Property contains all of the intellectual  property
necessary to operate the business of the Company as currently conducted.

              (b) The Company  exclusively  owns (or  otherwise has the right to
use the Intellectual  Property pursuant to a valid license,  sublicense or other
agreement), free and clear of all Liens, and has the unrestricted right (subject
to any such license terms, if applicable) to use, sell,  license,  or sublicense
all Intellectual Property.

              (c)  There  are no  issued  Patents,  registrations,  filings  and
applications for any Patents, Trademarks and Copyrights filed by the Company.

              (d)  There  are no  material  licenses,  sublicenses,  distributor
agreements and other  agreements or permissions  ("IP Licenses") under which the
Company is a (i) licensor, or (ii) licensee,  distributor,  or reseller,  except
such  licenses,  sublicenses  and other  agreements  relating  to  off-the-shelf
software which is  commercially  available on a retail basis for less than $1000
per license and $50,000 in the aggregate and used solely on the computers of the
Company ("Off-the-Shelf  Software"). To the knowledge of the Company, all of the
IP Licenses, if any, are valid, enforceable,  and in full force and effect, and,
with respect to the Company,  will continue to be on identical terms immediately
following the completion of the transactions contemplated by this Agreement.

              (e) All  products  made,  used or sold by the  Company  under  the
Patents have been marked with the proper patent notice.




              (f) All products and materials  made,  used or sold by the Company
containing   Trademarks  bear  the  proper  federal  registration  notice  where
permitted by law.

              (g)  All  works  encompassed  by the  Copyrights  and  used by the
Company have been marked with the proper copyright notice.

              (h)  To  the  Company's  knowledge,  upon  reasonable  inquiry  in
accordance with sound business practice and business judgment, all the Company's
Intellectual  Property rights are valid and  enforceable.  The Company has taken
all  reasonably   necessary  actions  to  maintain  and  protect  each  item  of
Intellectual Property owned by the Company.

              (i) The Company has taken all  reasonable  precautions  to protect
the secrecy, confidentiality, and value of its Trade Secrets and the proprietary
nature  and value of its  Intellectual  Property.  To the best of the  Company's
knowledge,  none of the Trade Secrets,  wherever located,  the value of which is
contingent upon maintenance of confidentiality  thereof,  have been disclosed to
any  employee,  representative  or agent of the Company or any other  person not
obligated  to  maintain   such  Trade  Secret  in   confidence   pursuant  to  a
confidentiality  agreement  entered  into with the  Company,  except as required
pursuant to the filing of a patent application by the Company.

              (j) The Company is diligently  prosecuting all Patent applications
it has filed, as instructed by patent counsel.  The Company is diligently filing
and  preparing to file Patent  applications  for all  inventions in a manner and
within a  sufficient  time  period to avoid  statutory  disqualification  of any
potential Patent application.

              (k) Unless  otherwise  disclosed  by the  Company or pursuant to a
current  license,  it is not  necessary  for the  Company's  business to use any
Intellectual Property owned by any present or past director,  officer,  employee
or consultant of the Company (or persons the Company presently intends to hire).
To the actual knowledge of the Company's executive  officers,  at no time during
the  conception  or reduction to practice of any of the  Company's  Intellectual
Property was any developer,  inventor or other  contributor to such Intellectual
Property  operating under any grants from any Governmental  Authority or subject
to any employment agreement,  invention and assignment,  nondisclosure agreement
or other Contractual  Obligation with any Person that could adversely affect the
Company's rights to its Intellectual Property.

              (l) To the knowledge of the Company,  upon  reasonable  inquiry in
accordance  with sound  business  practice  and business  judgment,  none of the
Intellectual  Property,  products or services owned, used, developed,  provided,
sold or licensed by the Company, or made for, used or sold by or licensed to the
Company by any person  infringes  upon or otherwise  violates  any  Intellectual
Property rights of others.

              (m) To the knowledge of the Company,  upon  reasonable  inquiry in
accordance  with sound  business  practice and business  judgment,  no Person is
infringing upon or otherwise  violating the Intellectual  Property rights of the
Company.

         6.10     Employee Benefit Plans.

              (a)  Neither  the  Company  nor any  entity  which is or was under
common control within the meaning of Section 414(b), (c), (m) or (o) of the Code
maintains or contributes to, or has within the preceding six years maintained or
contributed  to, or may have any liability with respect to any employee  benefit
plan subject to Title IV of Employee  Retirement Income Security Act of 1974, as
amended  ("ERISA"),  or Section 412 of the Code or any "multiple  employer plan"
within  the  meaning  of  the  Code  or  ERISA.   Each  employee  benefit  plan,
arrangement,   policy,  program,  agreement  or  commitment  which  the  Company
maintains,  contributes  to or may have any  liability  in respect  to (each,  a
"Plan") has been  established and administered in accordance with its terms, and
complies in form and in operation with the applicable requirements of ERISA, the
Code and other  applicable  Requirements  of Law.  No claim with  respect to the
administration  or the  investment of the assets of any Plan (other than routine
claims for benefits) is pending.  No event has occurred in connection with which
the  Company  or any Plan,  directly  or  indirectly,  could be  subject  to any
material  liability  under  ERISA,  the Code or any  other  law,  regulation  or
governmental  order applicable to any Plan, or under any agreement,  instrument,
statute,  rule of law or  regulation  pursuant to or under which the Company has
agreed to  indemnify  any person  against  liability  incurred  under,  or for a
violation or failure to satisfy the requirement of, any such statute, regulation
or  order.  The  Company  has no  liability,  whether  absolute  or  contingent,
including any obligations under any Plan, with respect to any  misclassification
of any person as an independent contractor rather than as an employee.




         (b) The Company does not have any  obligations to provide or any direct
or indirect  liability,  whether  contingent or  otherwise,  with respect to the
provision of health or death  benefits to or in respect of any former  employee,
except  as may be  required  pursuant  to  Section  4980B  of the  Code  and the
corresponding  provisions  of ERISA and the cost of which are fully paid by such
former employees.

         (c)  There are no  unfunded  obligations  under any Plan  which are not
fully reflected on the Financial Statements.

         6.11 Investment Company.  The Company is not an "investment company" or
an  "affiliated  person" of, or  "promoter" or  "principal  underwriter"  for an
investment company, within the meaning of the Investment Company Act of 1940, as
amended.

         6.12  Private  Offerings.   Assuming  the  truth  of  each  Purchaser's
representations and acknowledgments  contained in Section 5 hereof,  neither the
Company nor any Person  acting on its behalf (other than the  Purchasers,  as to
whom the Company makes no representations) has offered or sold the Securities by
means of any general  solicitation or general  advertising within the meaning of
Rule 502(c) under the Securities Act. The Company has not sold the Securities to
anyone other than the  subscribers to this  Agreement.  Each Security shall bear
substantially the same legend set forth in Section 8 hereof for at least so long
as required by the Securities Act.

         6.13  Broker's  or  Finder's  Commissions.  No finder,  broker,  agent,
financial  person or other  intermediary  has acted on behalf of the  Company in
connection with the sale of the Securities by the Company or the consummation of
this Agreement or any of the transactions  contemplated  hereby. The Company has
not had any direct or indirect  contact  with any  investment  banking  firm (or
similar firm) with respect to the offer of the  Securities by the Company to the
Purchasers or the Purchasers' subscriptions for the Securities.

         6.14  Disclosure.  The Transaction  Documents do not contain any untrue
statement of a material fact or omit to state a material fact necessary in order
to make  the  statements  contained  herein  or  therein,  in the  light  of the
circumstances  under which they were made, not misleading.  The Company does not
have any  knowledge  of any fact that has  specific  application  to the Company
(other than general economic or industry  conditions) and that can reasonably be
foreseen to cause a Material  Adverse  Effect that has not been set forth in the
Transaction Documents or the Commission Documents.

         The Company  certifies that each of the foregoing  representations  and
warranties  by the Company  sets forth in this Section 6 are true as of the date
hereof and shall survive such date as contemplated in Section 7.1.

         7.       Indemnification.

         7.1 The Company  agrees to indemnify and hold harmless the  Purchasers,
their affiliates and each of their respective directors,  officers,  general and
limited   partners,   principals,   agents  and  attorneys   (individually,   an
"Indemnified  Party"  and  collectively,  the  "Indemnified  Parties")  from and
against any and all  losses,  claims,  damages,  Liabilities,  costs  (including
reasonable attorneys' fees) and expenses  (collectively,  "Losses") to which any
Indemnified  Party may become  subject,  insofar as such Losses arise out of, in
any way  relate  to, or result  from (i) any  breach  of any  representation  or
warranty made by the Company contained in or made pursuant to this Agreement, or
(ii) the failure of the Company to fulfill any  agreement or covenant  contained
in or made pursuant to this Agreement. All of the representations and warranties
of the Company  made herein  shall  survive the  execution  and delivery of this
Agreement  until  the date  that is ninety  (90)  days  after the  filing by the
Company with the Commission of audited  financial  statements of the Company for
the fiscal year ending  January 31, 2004 (or, if such fiscal year changes and no
such audited consolidated financial statements are available, then the successor
fiscal  year),  except for (a) Sections  6.1  (Organization,  Good  Standing and
Qualification),  6.2  (Capitalization),  6.3  (Corporate  Power,  Authorization;
Enforceability),  6.12  (Private  Offerings)  and  6.13  (Broker's  or  Finder's
Commission), which representations and warranties shall survive indefinitely (or
if  indefinite  survival is not  permitted by law,  then for the maximum  period
permitted by applicable law), (b) Section 6.8 (Taxes),  which representation and
warranty  shall survive until the later to occur of (i) the lapse of the statute
of  limitations  with  respect  to the  assessment  of any  tax  to  which  such
representation  and  warranty  relates  (including  any  extensions  or  waivers
thereof)  and (ii) sixty (60) days after the final  administrative  or  judicial
determination of the Taxes to which such  representation  and warranty  relates,
and no claim with  respect to Section  6.8 may be asserted  thereafter  with the
exception of claims arising out of any fact, circumstance,  action or proceeding
to which the party  asserting  such claim  shall have given  notice to the other
parties to this Agreement  prior to the termination of such period of reasonable
belief that a tax liability will subsequently  arise therefrom,  and (c) Section
6.7  (Environmental  Matters),  which  representation and warranty shall survive
until the lapse of the applicable  statute of  limitations.  Except as set forth
herein,  all of the covenants,  agreements and obligations of the parties hereto
shall  survive  the  Closing  indefinitely  (or if  indefinite  survival  is not
permitted by law, then for the maximum period permitted by applicable law).




         7.2 Promptly after receipt by an Indemnified Party under Section 7.1 of
notice of any claim as to which  indemnity  may be  sought,  including,  without
limitation,  the commencement of any action or proceeding, the Indemnified Party
will, if a claim in respect thereof may be made against the  indemnifying  party
under this Section,  promptly  notify the  indemnifying  party in writing of the
commencement  thereof;  provided that the failure of the Indemnified Party to so
notify the indemnifying  party will not relieve the indemnifying  party from its
obligations  under  this  Section  unless,  and only to the  extent  that,  such
omission results in the indemnifying party's forfeiture of substantive rights or
defenses or being materially  prejudiced by the Indemnified  Person's failure to
give such  notice.  In case any  action or  proceeding  is brought  against  any
Indemnified  Party, and it notifies the  indemnifying  party of the commencement
thereof,  the indemnifying party shall be entitled to assume the defense thereof
at its own expense,  with counsel  satisfactory to such Indemnified Party in its
reasonable   approval   (which   approval   will  not  be  withheld  or  delayed
unreasonably);  provided,  however,  that any Indemnified  Party may, at its own
expense,  retain  separate  counsel to  participate  in such  defense at its own
expense.  After notice from the indemnifying  party to the Indemnified  Party of
its election to so assume the defense thereof,  the indemnifying  party will not
be Liable to the  Indemnified  Party  under that  Section 7 for any legal or any
other expenses subsequently incurred by the Indemnified Party in connection with
the  defense  thereof  (other than  reasonable  costs of  investigation)  unless
incurred at the written request of the indemnifying  party.  Notwithstanding the
above,  the  Indemnified  Party will have the right to employ counsel of its own
choice in any action or proceeding (and be reimbursed by the indemnifying  party
for the reasonable fees and expenses of the counsel and other  reasonable  costs
of the defense) if, in the written opinion of such Indemnified  Party's counsel,
representation  of  the  Indemnified  Party  by  the  counsel  retained  by  the
indemnifying  party would be inappropriate due to actual or potential  differing
interests  or  conflicts  between  the  Indemnified  Party and any  other  party
represented  by  the  counsel  in  the  action;  provided,   however,  that  the
indemnifying  party will not in connection  with any one action or proceeding or
separate but  substantially  similar  actions or proceedings  arising out of the
same general allegations, be Liable for the reasonable fees and expenses of more
than one separate  firm of attorneys  at any time for all  Indemnified  Parties,
except to the extent that local  counsel,  in addition  to regular  counsel,  is
required in order to effectively  defend  against the action or  proceeding.  An
indemnifying  party  will  not  be  Liable  to any  Indemnified  Party  for  any
settlement or entry of judgment  concerning  any action or  proceeding  effected
without  the  consent of the  indemnifying  party,  which  consent  shall not be
unreasonably  withheld.  The indemnifying party agrees that it will not, without
the prior  written  consent of the  Indemnified  Party,  settle,  compromise  or
consent to the entry of any judgment in any pending or threatened claim relating
to the matters  contemplated hereby (if any Indemnified Party is a party thereto
or has  been  actually  threatened  to be  made a  party  thereto)  unless  such
settlement,  compromise  or consent  includes an  unconditional  release of each
Indemnified  Party  from all  liability  arising  or that may  arise out of such
claim.  The  rights  accorded  to an  Indemnified  Party  hereunder  shall be in
addition  to any rights  that any  Indemnified  Party may have at common law, by
separate agreement or otherwise;  provided,  however,  that  notwithstanding the
foregoing or anything to the contrary  contained in this Agreement,  (a) nothing
in this Section 7 shall restrict or limit any rights that any Indemnified  Party
may  have to seek  equitable  relief  and (b) this  Section  7 shall be the sole
remedy for any breach of the Company's  representations and warranties contained
in  Section 6 except  with  respect  to claims  arising  out of fraud or willful
misconduct.

         8. Covenants.

         8.1 Use of  Proceeds.  The  Company  will use the  proceeds  from  this
Offering for general corporate purposes.

         8.2 Conduct of the Company's  Business.  Except as contemplated by this
Agreement,  during the period  from the date  hereof to the  Closing  Date,  the
Company will conduct its business and operations  solely in the ordinary  course
of business consistent with past practice and use reasonable  commercial efforts
to keep  available  the services of its officers and  employees and preserve its
current relationships with customers, suppliers, licensors, creditors and others
having business dealings with it.

         8.3  Reasonable  Best Efforts.  Subject to the terms and  conditions of
this Agreement,  each of the parties hereto will use its reasonable best efforts
to take, or cause to be taken, all actions,  and to do, or cause to be done, all
things  necessary,  proper or advisable under applicable laws and regulations to
consummate  the  transactions  contemplated  by this  Agreement  at the earliest
practicable date.




         8.4      Tax Matters.

         (a) The  Company  covenants  that it will use  commercially  reasonable
efforts not to become a USRPHC at any time while any  Purchaser  owns any of the
Securities.

         (c) In the event that a Purchaser  desires to sell or dispose of any of
the Securities or Common Stock  underlying  such  Securities as permitted  under
this  Agreement  and  applicable  law,  and upon demand by such  Purchaser,  the
Company  agrees to deliver  to such  Purchaser  a letter  (the  "Letter")  which
complies  with   Sections   1.1445-2(c)(3)   and   1.897-2(h)  of  the  Treasury
Regulations,  addressed to such Purchaser, stating whether or not the Company is
a USRPHC.  The Letter shall be delivered to the Purchaser one business day prior
to the close of any sale or disposition of the Securities or Conversion Stock by
the  Purchaser  (the  "Delivery  Date").  The  Letter  shall  be dated as of the
Delivery Date and signed by a corporate  officer who must verify under penalties
of perjury that the statement is correct to his knowledge and belief pursuant to
Section 1.897-2(h) of the Treasury Regulations.

         8.5 Piggyback Registration Rights

              (a) Right to Piggyback.  Whenever the Company proposes to register
any of its securities  under the Securities Act (other than pursuant to a Demand
Registration,  or a registration  on Form S-4 or S-8 or any successor or similar
forms) and the registration  form to be used may be used for the registration of
Registrable Securities, whether or not for sale for its own account, the Company
will give prompt written notice (but in no event less than twenty five (25) days
before the  anticipated  filing date) to all holders of Registrable  Securities,
and such notice shall describe the proposed  registration  and  distribution and
offer to all holders of Registrable  Securities the  opportunity to register the
number of  Registrable  Securities as each such holder may request.  The Company
will include in such  registration  all  Registrable  Securities with respect to
which the Company has received  written  requests for inclusion  therein  within
fifteen  (15)  days  after  the  holders'  receipt  of the  Company's  notice (a
"Piggyback Registration").

              (b) Reasonable Efforts.  The Company shall use all reasonable best
efforts  to  cause  the  managing  underwriter  or  underwriters  of a  proposed
underwritten  offering  to permit the  Registrable  Securities  requested  to be
included  in a  Piggyback  Registration  to be  included  on the same  terms and
conditions as any similar securities of the Company or any other security holder
included therein and to permit the sale or other disposition of such Registrable
Securities in accordance with the intended method of distribution thereof.

              (c)  Withdrawal.  Any  Designated  Holder  shall have the right to
withdraw  its  request  for  inclusion  of  its  Registrable  Securities  in any
Registration  Statement pursuant to this Section 8.5 by giving written notice to
the  Company of its  request to  withdraw;  provided,  that in the event of such
withdrawal (other than pursuant to Section 8.5(f) hereof,  the Company shall not
be required to reimburse  such holder for fees and expenses  hereof  incurred by
such  holder  prior to such  withdrawal,  unless  such  withdrawal  was due to a
material  adverse  change to the  Company.  The Company may withdraw a Piggyback
Registration at any time prior to the time it becomes effective.

              (d) Priority in Registrations.  If a Piggyback  Registration is an
underwritten  primary  registration  on behalf of the Company,  and the managing
underwriters  advise the  Company in writing  (with a copy to each party  hereto
requesting  registration  of Registrable  Securities)  that in their opinion the
number of Registrable  Securities  requested to be included on a secondary basis
in such  registration  exceeds  the  number  which can be sold in such  offering
without materially and adversely  affecting the marketability of such primary or
secondary  offering (the  "Company  Offering  Quantity"),  then the Company will
include in such registration securities in the following priority:

                  (i)      First,  the Company will include the  securities  the
Company proposes to sell.

                  (ii)     Second,  the Company  will  include  all  Registrable
Securities  requested to be included by any Designated Holder, and if the number
of such  Designated  Holders'  securities  requested to be included  exceeds the
Company  Offering  Quantity,  then the  Company  shall  include  only  each such
requesting  Designated  Holders'  pro rata  share of the  shares  available  for
registration  by the Purchaser,  based on the amount of securities  held by such
holder, on an as converted basis.

              (e) Cutback.  If, as a result of the proration  provisions of this
Section  8.5,  any  Designated  Holders  shall not be  entitled  to include  all
Registrable  Securities in a Piggyback Registration that such Designated Holders
has  requested to be included,  such holder may elect to withdraw his request to
include  Registrable  Securities in such  registration  but the Company shall be
required to reimburse such holder for the fees and expenses  hereof  incurred by
such holder prior to such withdrawal.





         9. FOR RESIDENTS OF ALL STATES:  NEITHER THE SECURITIES  OFFERED HEREBY
OR THE  SECURITIES  INTO  WHICH  SUCH  SECURITIES  MAY BE  CONVERTED  HAVE  BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,  OR THE SECURITIES LAWS
OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE ON  EXEMPTIONS  FROM THE
REGISTRATION  REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT
TO  RESTRICTIONS  ON  TRANSFERABILITY  AND RESALE AND MAY NOT BE  TRANSFERRED OR
RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION
OR EXEMPTION THEREFROM.  INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO
BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

         10. No Waiver.

         Notwithstanding any of the representations, warranties, acknowledgments
or agreements made herein by the Purchasers, the Purchasers do not thereby or in
any manner waive any rights  granted to the  Purchasers  under  federal or state
securities laws.

         11.      Miscellaneous.

         11.1 Notices.  Any notice or other communication given hereunder by any
party  hereto  to any other  party  hereto  shall be in  writing  and  delivered
personally or by facsimile  transmission or sent by registered or certified mail
or by any express mail or overnight courier service, postage or fees prepaid:

                  If to the Company:

                           Enhance Biotech, Inc.
                           16th Floor, 666 Third Avenue
                           New York, New York  10017
                           Attention:  Christopher Every, CEO
                           Telephone:  (212) 561 1716
                           Facsimile:  (212) 697 1985

                  If to the Purchasers:

                           To  each  Purchaser  at  such  Purchaser's  name  and
                           address  set  forth  on the  signature  page  to this
                           Agreement.

              Any  notice  that  is   delivered   personally   or  by  facsimile
transmission  in the manner  provided  herein  shall be deemed to have been duly
given to the party to whom it is directed  upon actual  receipt by such party or
its agent.  Any notice  that is  addressed  and mailed or sent by courier in the
manner herein provided shall be conclusively presumed to have been duly given to
the party to which it is addressed  at the close of business,  local time of the
recipient,  on the fourth business day after the day it is so placed in the mail
or, if earlier, the time of actual receipt.

         11.2  Successors  and Assigns.  This Agreement will be binding upon and
inure to the benefit of the parties hereto and to their respective heirs,  legal
representatives, successors and assigns, provided, that no party may assign this
Agreement without the prior written consent of the other party, such consent not
to be unreasonably withheld; provided, further, that a Purchaser may assign this
Agreement to its  wholly-owned  affiliates  without  consent;  provided that any
transfer of Securities or shares of Common Stock underlying such Securities must
be in compliance with the Transaction Documents and all applicable law.




         11.3 Entire  Agreement.  This Agreement sets forth the entire agreement
and  understanding  among the parties as to the subject matter hereof and merges
and supersedes all prior  discussions,  agreements and understandings of any and
every nature among them; provided that any confidentiality agreement between the
Company and any Purchaser shall remain in effect.  This Agreement may be amended
only by mutual  written  agreement  of the Company and a majority in interest of
the Purchasers, and the Company may take any action herein prohibited or omit to
take any action  herein  required to be  performed  by it, and any breach of any
covenant,  agreement,  warranty  or  representation  may be waived,  only if the
Company has obtained the written consent or waiver of the Purchasers  purchasing
a majority of the Securities offered hereby.

         11.4 Governing  Law. This Agreement  shall be governed by and construed
in  accordance  with the laws of the State of New York with respect to contracts
made and to be fully performed therein,  without regard to the conflicts of laws
principles thereof.  The parties hereto hereby agree that any suit or proceeding
arising under this  Agreement,  or in connection  with the  consummation  of the
transactions  contemplated hereby, shall be brought solely in a federal or state
court  located in the County of New York and State of New York. By its execution
hereof,  both the  Company and the  Purchasers  hereby  consent and  irrevocably
submit to the in personam  jurisdiction  of the federal and state courts located
in the  County of New York and State of New York and agree  that any  process in
any suit or  proceeding  commenced  in such courts under this  Agreement  may be
served upon it  personally or by certified or registered  mail,  return  receipt
requested,  or by Federal Express or other courier service,  with the same force
and effect as if personally  served upon the applicable party in New York and in
the city or county in which such other court is located. The parties hereto each
waive any claim that any such  jurisdiction  is not a  convenient  forum for any
such suit or proceeding and any defense of lack of in personam jurisdiction with
respect thereto.

         11.5 Severability. The holding of any provision of this Agreement to be
invalid or  unenforceable by a court of competent  jurisdiction  will not affect
any other  provision  of this  Agreement,  which  will  remain in full force and
effect.  If any provision of this  Agreement is declared by a court of competent
jurisdiction  to be invalid,  illegal or incapable of being enforced in whole or
in part, the provision  will be  interpreted so as to remain  enforceable to the
maximum  extent  permissible  consistent  with  applicable law and the remaining
conditions and provisions or portions thereof will  nevertheless  remain in full
force and  effect  and  enforceable  to the  extent  they are  valid,  legal and
enforceable,  and no provisions will be deemed dependent upon any other covenant
or provision unless so expressed herein.

         11.6 No Waiver.  A waiver by either party of a breach of any  provision
of this  Agreement  will  not  operate,  or be  construed,  as a  waiver  of any
subsequent breach by that same party.

         11.7 Further  Assurances.  The parties agree to execute and deliver all
further documents,  agreements and instruments and take further action as may be
necessary or appropriate to carry out the purposes and intent of this Agreement.

         11.8  Counterparts.  This  Agreement  may be  executed  in two or  more
counterparts,  each of which will be deemed an  original,  but all of which will
together constitute the same instrument.

         11.9 No Third Party Beneficiaries. Nothing in this Agreement creates in
any Person not a party to this Agreement any legal or equitable right, remedy or
claim under this Agreement,  and this Agreement is for the exclusive  benefit of
the parties hereto.  The parties expressly  recognize that this Agreement is not
intended to create a  partnership,  joint venture or other  similar  arrangement
between any of the parties or their respective affiliates.

         11.10  Headings.   The  headings  in  this  Agreement  are  solely  for
convenience  of reference  and shall be given no effect in the  construction  or
interpretation of this Agreement.

         11.11 Publicity  Restrictions.  Except as may be required by applicable
Requirements  of Law, no  Purchaser  shall  issue a publicity  release or public
announcement or otherwise make any disclosure  concerning  this  Agreement,  the
transactions contemplated hereby without prior approval by the Company; provided
that each  Purchaser  may disclose on its  worldwide  web pages and its offering
materials,  if any,  the name of the  Company,  the name of the Chief  Executive
Officer of the  Company,  a brief  description  of the  business  of the Company
consistent  with the  Commission  Documents or the Company's  press  releases or
other public  statements,  the Company's  logo and the aggregate  amount of such
Purchaser's  investment in the Company without having any ownership interest in,
or other right to use of, any of the same,  and without  taking any action which
would adversely  affect the Company's  interest in such logo or omitting to take
any action  necessary to protect the same.  If any  announcement  is required by
applicable law or the rules of any  securities  exchange or market on which such
shares of  Common  Stock are  traded  to be made by any party  hereto,  prior to
making such announcement such party will deliver a draft of such announcement to
the  Company  and shall  give the  Company  reasonable  opportunity  to  comment
thereon.  The parties agree to attribute and otherwise indicate ownership of the
other party's trademarks and logos.




         11.12  Certification.  Each Purchaser certifies that such Purchaser has
read this entire  Agreement and that every  statement on such  Purchaser's  part
made and set forth herein is true and complete.

                 [Remainder of page intentionally left blank.]







         IN WITNESS  WHEREOF,  the  undersigned  has  executed  this  Securities
Purchase  Agreement on the date his signature has been  subscribed  and sworn to
below.

The shares of Common  Stock and the common  stock  purchase  warrants  are to be
issued in:


                                                          
                                                             ----------------------------------------------------------
                                                             Print Name of Investor

                                                                                shares of Common Stock subscribed for
                                                             ------------------
____ individual name
                                                             Subscription  price paid herewith:
                                                             $                  (being $1.50 x the number of shares
                                                              -----------------
____ tenants in the entirety                                 of Common Stock listed above)


                                                             ----------------------------------------------------------
____ corporation (an officer must sign)                      Print Name of Joint Investor
                                                             (if applicable)


                                                             ----------------------------------------------------------
____ partnership (all general partners must sign)            Signature of Investor


                                                             ----------------------------------------------------------
____ trust                                                   Signature of Joint Investor


                                                             ----------------------------------------------------------
____ limited liability company

                                                             ----------------------------------------------------------
                                                             (with a copy to:)

                                                             ----------------------------------------------------------

                                                             ----------------------------------------------------------

                                                             ----------------------------------------------------------
                                                             Address of Investor



Accepted as of the ___ day of __________,  2003 as to _______________  shares of
Common Stock;  Subscription price accepted being $______________,  being $1.50 x
the number of shares of Common Stock as to which this Subscription is accepted:

ENHANCE BIOTECH, INC.

By: ___________________________________________
Name:
Title: